More than 200 researchers attended the Miller Office of Research’s Shared Resources Fair on February 17, which was followed by a Collaborative Research Exchange Forum (CREF) on drug discovery.
A team of researchers led by Claes Wahlestedt, M.D., Ph.D., the Miller School’s associate dean for therapeutic innovation, has pinpointed a “master” regulatory molecule in the brain that is altered in people with schizophrenia. The finding could facilitate the development of better drugs for the debilitating psychiatric disorder that affects an estimated one percent of the world’s population.